Lucid Diagnostics Inc.: insider trades · United States · SEC (Form 4)

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a U.S.-based, commercial-stage medical diagnostics company focused on the prevention of esophageal cancer. Headquartered in New York, United States, and listed on the NASDAQ market, Lucid develops non-invasive technologies intended to detect esophageal precancer earlier, with the goal of intervening before disease progresses to invasive cancer. The company is a subsidiary of PAVmed Inc., which gives it the backing of a broader commercial-stage medtech platform. ([luciddx.com](https://www.luciddx.com/company?utm_source=openai)) Lucid’s history dates back to 2018, when it finalized a definitive licensing agreement with Case Western Reserve University covering the core technology behind its lead products. Since then, the company has reached several important milestones: FDA 510(k) clearance for EsoCheck in 2019, the commercial launch of EsoGuard as a laboratory-developed test in 2019, FDA Breakthrough Device designation for EsoGuard in 2020, and a Nasdaq IPO in 2021. Lucid also operates LucidDx Labs, a CLIA-certified, CAP-accredited laboratory that supports clinical testing operations. ([luciddx.com](https://www.luciddx.com/company?utm_source=openai)) The business is built around two complementary products. EsoCheck is an esophageal cell collection device designed for a brief, non-invasive office procedure. EsoGuard is the accompanying DNA test that analyzes the collected cells to help identify patients at risk of Barrett’s esophagus and other forms of esophageal precancer. Together, these products are positioned as a screening alternative to traditional upper endoscopy for at-risk patients, supporting Lucid’s broader prevention-focused narrative and its attempt to convert clinical adoption into recurring test-volume growth. ([ir.luciddx.com](https://ir.luciddx.com/2025-12-09-Lucid-Diagnostics-Announces-Positive-Data-from-the-Largest-Reported-Real-World-Experience-of-Esophageal-Precancer-Detection?utm_source=openai)) From a competitive perspective, Lucid occupies a specialized niche in early esophageal precancer detection. Its differentiation is based on a non-endoscopic workflow, proprietary sampling and molecular testing, and a growing body of clinical and real-world evidence. The company has highlighted support from updated NCCN guidance and American College of Gastroenterology recommendations that reference non-endoscopic biomarker testing as an acceptable alternative to invasive endoscopy in relevant settings. That said, the investment case still reflects a developing commercial-stage diagnostics company rather than a mature, scaled medtech franchise. ([ir.luciddx.com](https://ir.luciddx.com/2025-03-20-Lucid-Diagnostics-Announces-Updated-National-Comprehensive-Cancer-Network-R-NCCN-Guidelines-Now-Include-Esophageal-Precancer-Screening?utm_source=openai)) Operationally, Lucid is primarily U.S.-centric, with corporate headquarters in New York and laboratory operations in California. Recent news flow has been constructive: the company reported growing EsoGuard-related revenues, expanding health-system partnerships, stronger payer engagement, and progress in Medicare coverage discussions. In 2026, Lucid also reported a stronger cash position after recent equity financing, supporting its operating runway. For investors in French-speaking markets, LUCD is best viewed as a high-risk, high-upside U.S. NASDAQ-listed medtech name tied to the long-term adoption of preventive esophageal cancer screening. ([ir.luciddx.com](https://ir.luciddx.com/2026-05-14-Lucid-Diagnostics-Provides-Business-Update-and-Reports-First-Quarter-2026-Financial-Results?utm_source=openai))